Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT02457910

Public ClinicalTrials.gov record NCT02457910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This partially randomized phase Ib/II trial studies the side effects and best dose of taselisib when given together with enzalutamide and to see how well they work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body. Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of tumor cells by blocking the androgen receptor from working. Giving taselisib with enzalutamide may be a better treatment for patients with breast cancer.

Study identification

NCT ID: NCT02457910
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

Other · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2015
Primary completion: Nov 30, 2018
Completion: Aug 7, 2022
Last update posted: Aug 21, 2022

2015 – 2022

United States locations

U.S. sites: 12
U.S. states: 12
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of Alabama, Birmingham	Birmingham	Alabama	35249	—
Georgetown University	Washington D.C.	District of Columbia	20007	—
University of Chicago	Chicago	Illinois	60637	—
Indiana University	Indianapolis	Indiana	47405	—
John Hopkins University	Baltimore	Maryland	21218	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
University of Michigan	Ann Arbor	Michigan	—	—
Mayo Clinic	Rochester	Minnesota	55905	—
University of North Carolina	Chapel Hill	North Carolina	27599	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15260	—
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	—
Baylor Breast Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02457910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 21, 2022 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02457910 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →